PTPN11 and myelodysplastic syndrome: Somatic gain-of-function mutations of PTPN11 are identified in patients with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia, and de novo AML, especially in the FAB M4/M5 subtypes [48,49].